Document Type
Article
Publication Date
8-17-2017
Abstract
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for this disease state. The optimal sequencing of these agents is unclear as there are no large-scale head-to-head comparisons. Clinicians must familiarize themselves with the most recent studies as well as drug toxicities to determine the best treatment option for their patients. In this review, we focus on the development of cabazitaxel for mCRPC, evaluate its efficacy, and highlight key strategies for toxicity management. Additionally, we summarize the studies that address cabazitaxel treatment sequencing and optimal dosing schedule.
Recommended Citation
Patel, Sheel and Hoffman-Censits, Jean, "Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations." (2017). Department of Medical Oncology Faculty Papers. Paper 86.
https://jdc.jefferson.edu/medoncfp/86
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License
PubMed ID
28860817
Language
English
Comments
This article has been peer reviewed. It is the author’s final published version in OncoTargets and Therapy, Volume 10, August 2017, Pages 4089-4098.
The published version is available at https://doi.org/10.2147/OTT.S103532. Copyright © Patel & Hoffman-Censits